TCGA-DK-AA71-01A-31R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.63337714
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.540
- MYC_TARGETS_V1+0.520
- DNA_REPAIR+0.350
- MYC_TARGETS_V2+0.350
- FATTY_ACID_METABOLISM+0.310
- MTORC1_SIGNALING+0.280
- PEROXISOME+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- P53_PATHWAY+0.240
- PANCREAS_BETA_CELLS+0.240
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- ALLOGRAFT_REJECTION-0.360
- IL2_STAT5_SIGNALING-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- TGF_BETA_SIGNALING-0.300
- ANGIOGENESIS-0.280
- KRAS_SIGNALING_UP-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.906 |
| 2 | ERR2278847 | — | — | 0.899 |
| 3 | SRR8518383 | — | E | 0.895 |
| 4 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.894 |
| 5 | ERR2278860 | — | — | 0.891 |
| 6 | TCGA-XF-A8HB-01A-11R-A36F-07 | — | — | 0.891 |
| 7 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.889 |
| 8 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.889 |
| 9 | SRR10900021 | — | — | 0.884 |
| 10 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |